GREEN LIFESCIENCE CO., LTD.
Financials
Valuation Metrics
GREEN LIFESCIENCE CO., LTD.'s Market Cap is ₩417B. At end of 2025 it was ₩580B. Ranked #1825 of 2,405 in KR market (top 76%), #1126 of 1,627 on KOSDAQ (top 69%), #194 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 84%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 41.70B KRW | KR#1,825/2,405 Sec#194/231 |
| Revenue | 58.57B KRW | KR#1,705/2,405 Sec#115/231 |
| Net Income | 7.36B KRW | KR#1,075/2,405 Sec#68/231 |
| Total Assets | 59.36B KRW | KR#2,108/2,405 Sec#185/231 |
| Net Assets | 44.85B KRW | KR#1,969/2,405 Sec#170/231 |
| Employees | 65 | KR#1,923/2,405 Sec#169/231 |
| Value | ||
| P/E | 5.67x | KR#485/2,405 Sec#19/231 |
| P/B | 0.93x | KR#1,467/2,405 Sec#90/231 |
| P/S | 0.71x | KR#1,209/2,405 Sec#63/231 |
| EV/EBITDA | 9.39x | KR#617/2,405 Sec#28/231 |
| FCF Yield | -1.19% | KR—/2,405 Sec—/231 |
| Profitability | ||
| ROE | 16.40% | KR#261/2,405 Sec#16/231 |
| ROA | 12.39% | KR#177/2,405 Sec#14/231 |
| Op. Margin | 6.27% | KR#800/2,405 Sec#63/231 |
| Revenue Growth | 111.03% | KR#75/2,405 Sec#14/231 |
| Financial Health | ||
| Debt Ratio | 32.34% | KR#634/2,405 Sec#74/231 |
| Total Debt | 7.00B KRW | KR#1,712/2,405 Sec#159/231 |
| FCF | -495.7M KRW | KR#1,251/2,405 Sec#96/231 |
| Cash | 14.22B KRW | KR#1,471/2,405 Sec#118/231 |
| Current Ratio | 2.91x | KR#575/2,405 Sec#77/231 |
| Net Debt/EBITDA | -1.97x | KR#238/2,405 Sec#10/231 |
| Dividend | ||
| Div. Growth | 0.00% | KR—/2,405 Sec—/231 |
| Performance | ||
| 1Y Return | -32.41% | KR#1,177/2,405 Sec#86/231 |
| 1M Return | -8.95% | KR#1,061/2,405 Sec#101/231 |
| From 52W High | -54.58% | KR#1,378/2,405 Sec#111/231 |
| 1Y MDD | -57.31% | KR#1,289/2,405 Sec#110/231 |
| Trading | ||
| Volume | 110,544 shares | KR#597/2,405 Sec#61/231 |
| Trading Value | 227.4M KRW | KR#1,074/2,405 Sec#119/231 |
| Foreign Own. | 2.46% | KR#1,468/2,405 Sec#140/231 |
| Per Share | ||
| EPS | 368 KRW | KR#1,093/2,405 Sec#76/231 |
| BPS | 2,243 KRW | KR#2,022/2,405 Sec#167/231 |
Company Info
Green Life Science, established in 2005 and headquartered in Yeosu-si, Jeollanam-do, is a specialized manufacturer of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates, listed on the KOSDAQ market in 2009. The company pioneered the development of EDP-CL, a piperacillin-based antibiotic intermediate, in Korea, supplying it to global pharmaceutical companies, and its synthesis plant was the first in Korea to receive U.S. FDA approval. It produces various APIs and raw material intermediates, including DSC for HIV treatment and antibiotic intermediate AM19, while maintaining a quality management system compliant with cGMP standards.